PALO ALTO, Calif., February 4, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company SCLX “Scilex”))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. SRNE “Sorrento”))), an innovative, revenue-generating company focused on the acquisition, development and commercialization of non-opioid pain management products for the management of acute and chronic pain, announced that its first all-virtual AGM (the ” Meeting”) is scheduled to be held at 9 a.m. PST on April 6, 2023. Scilex also announced that its Board of Directors has designated the close of business as March 6, 2023 as the record date (the “Record Date”) for determining stockholders who entitled to give notice and vote at the meeting.

About Scilex Holding Company

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative, revenue-generating company focused on the acquisition, development and commercialization of non-opioid pain management products for the management of acute and chronic pain. Scilex is uncompromisingly striving to become the world leader in pain management, committed to social, environmental, economic and ethical principles to responsibly develop pharmaceutical products to maximize the quality of life. Results of the pivotal Phase III study CLEAR program for SEMDEXA^TMits novel non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex has applied for breakthrough therapy designation and expects to request priority review for SEMDEXA^TM to treat sciatica. Scilex targets indications with high unmet need and high market opportunity with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex brought its first commercial product to market in October 2018, in-licensed a commercial product in June 2022 and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, as well as a Phase 2 and a Phase 1 candidate . Its commercial product,…